Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.

Stromberg, J S; Martinez, A A; Horwitz, E M; Gustafson, G S; Gonzalez, J A; Spencer, W F; Brabbins, D S; Dmuchowski, C F; Hollander, J B; Vicini, F A

Stromberg, J S; Martinez, A A; Horwitz, E M; Gustafson, G S; Gonzalez, J A; Spencer, W F; Brabbins, D S; Dmuchowski, C F; Hollander, J B; Vicini, F A.

Affiliation

Stromberg JS; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.

Cancer J Sci Am ; 3(6): 346-52, 1997.

Article in En | MEDLINE | ID: mdl-9403047

Subject(s)

Brachytherapy/methods; Iridium Radioisotopes/therapeutic use; Prostate-Specific Antigen/metabolism; Prostatic Neoplasms/metabolism; Prostatic Neoplasms/radiotherapy; Aged; Aged, 80 and over; Dose-Response Relationship, Radiation; Humans; Male; Middle Aged; Neoplasm Staging

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Iridium Radioisotopes / Prostate-Specific Antigen Type of study: Prognostic_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Cancer J Sci Am Journal subject: NEOPLASIAS Year: 1997 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links